葛兰素史克（GSK）股价下跌5.3%，原因是其药物Blenrep未能获得美国食品药品监督管理局（FDA）顾问委员会的支持。

Core Viewpoint - GSK's stock price fell by 5.3% due to the lack of support from the FDA advisory committee for its drug Blenrep [1] Company Summary - GSK's drug Blenrep did not receive backing from the FDA advisory committee, leading to a significant decline in the company's stock price [1]